News & Events

• BVI heads to EURETINA 2026 with a focused program highlighting the European launch of Virtuoso for vitreoretinal surgery.
• Hands-on wet labs, live demonstrations and a dedicated launch event will introduce retina specialists to BVI's next-generation surgical platform.

WALTHAM, Mass., September 17, 2026 — As retina specialists from around the world prepare to gather in Vienna for the 26th EURETINA Congress, BVI, a leading global ophthalmic device company, is set to showcase its continued commitment to advancing vitreoretinal surgery through innovative technology, surgeon collaboration and hands-on clinical experience. Read More

• Next-generation platform brings advanced fluidics, intelligent ultrasound delivery, advanced anterior vitrectomy, and streamlined workflow to cataract surgery.
• The European launch follows Virtuoso’s CE Mark certification under the European Union Medical Device Regulation and its presentation at ESCRS 2026

WALTHAM, Mass., September 9th, 2026 — BVI, a leading global ophthalmic device company, today announced the commercial launch of Virtuoso across Europe as part of its debut at the 2026 European Society of Cataract and Refractive Surgeons (ESCRS) Congress in London. Read More

• BVI heads to ESCRS 2026 with a comprehensive program centered on innovation, education and surgeon collaboration.
• European launch of Virtuoso and global availability of the complete ISOPURE SERENITY portfolio highlight a congress agenda featuring wet labs, educational sessions and peer-to-peer clinical engagement.

WALTHAM, Mass., August 19^th, 2026 — As the global ophthalmic community turns its attention to London for the 2026 European Society of Cataract and Refractive Surgeons (ESCRS) Congress, BVI, a leading global ophthalmic device company, is preparing to showcase how advanced technology, expanded cataract solutions, surgeon education and clinical collaboration come together to help shape the future of ophthalmic surgery. Read More

• New facility expands opportunities for hands-on learning, professional development, and clinical collaboration.
• BVI plans to expand the Hub's educational offerings through structured programs covering cataract surgery, glaucoma and vitreoretinal procedures, premium intraocular lenses, and practice development.

SANT CUGAT, Spain, June 15^th, 2026 — As ophthalmology becomes increasingly specialized and technology-driven, demand for practical surgical education continues to grow. To support that need, BVI today announced the opening of the BVI Experience Hub, a dedicated facility designed to support ophthalmic training, professional development, and clinical collaboration for surgeons and clinical teams from Europe and around the world. Read More

• The council will serve as an advisory group, guiding BVI on market insights, clinical practice and surgical education across Europe.
• The initiative builds on the momentum of BVI’s US Surgical Leadership Council, extending its collaborative model to key European markets. Read More

• CE Mark under the European Union Medical Device Regulation (EU MDR) achieved for Virtuoso®, BVI’s first dual-function phaco-vitrectomy platform designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
• First patient successfully treated at LMU Klinikum in Munich, Germany, in December 2025. This milestone builds on Virtuoso®’s presence across key 2025 industry forums, including EURETINA, ESCRS, and FloRETINA, and continued into 2026 at the Munich Retina Meeting, where the platform was featured in its first live surgery, reinforcing its design focus on fluidics stability, workflow efficiency, and the real-world demands of ophthalmic surgery.

WALTHAM, Mass., April 20th, 2026 — BVI, a global leader in ophthalmic device innovation, today announced that Virtuoso® has received the CE Mark under the European Union Medical Device Regulation (EU MDR), enabling commercialization across markets recognizing the CE Mark. Virtuoso® is BVI’s next-generation phaco-vitrectomy surgical platform, a dual-function system designed to support both cataract and vitreoretinal procedures on a single, integrated platform. Read More

Waltham, MA., January 19th, 2026 – BVI, a global leader in the ophthalmic device market, announced today the appointment of Jim Hollingshead as President & Chief Executive Officer. Hollingshead succeeds Shervin Korangy, who will continue to serve as an advisor to BVI and begin a new role as senior advisor to TPG Capital.  Read More

• BVI announces Virtuoso®, its first dual-function phaco-vitrectomy system designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
• European debut planned for 2025 Global ophthalmic congresses in Europe (Euretina and ESCRS).  

Waltham, Mass., September 3, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the European market unveiling of its innovative phaco-vitrectomy surgical platform, Virtuoso®, a dual-function system designed for both cataract and vitreoretinal procedures. Read More

• BVI received four awards in the 2025 Medical Device Network Excellence Awards—for Innovation, Product Launches, R&D, and Investments—recognizing its leadership in advancing ophthalmic technology and global growth.
• Key achievements include the launch of SERENITY IOLs with ISOFOCAL technology, FDA clearance of the Leos™ glaucoma system, and a $1 billion capital raise supporting strategic expansion and continued innovation.

WALTHAM, Mass., July 9th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, has been recognized with four prestigious accolades in the 2025 Medical Device Network Excellence Awards. The company earned top honors in Innovation, Research and Development, Investments, and Product Launches, underscoring its leadership in advancing eye care technology, strategic growth, and breakthrough product development. Read More

• Positions company for several new product launches and scaling of operations to meet rising demand globally
• $1 billion of new capital raised to refinance debt and fund accelerated growth

Waltham, MA, March 10, 2025 – BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the completion of a $1 billion strategic capital raise in partnership with TPG, a leading global alternative asset management firm. This investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, strengthens the company’s financial position as it looks to accelerate product innovation and expand its global footprint. Read More

• EyeXchange Solutions connects experienced and emerging surgeons across cataract, glaucoma, and retina specialties to share insights, refine techniques, and address complex cases.

• BVI Medical aims to facilitate a collaborative forum fostering learning in ophthalmology through video series, engaging email discussions, and interactive quizzes.

Waltham, MA, January 31st, 2024 - BVI Medical, a diversified global ophthalmic device company committed to advancing eye surgery and improving patients’ vision, is excited to introduce EyeXchange Solutions. This new platform is designed to advance vision care through a comprehensive program of educational resources and clinical support, empowering surgical decisions, enhancing provider experiences, reducing the economic burden on healthcare systems, and optimizing patient care in cataract, glaucoma, and retina specialties. Read More

BVI to Launch New SERENITY and SERENITY Toric Premium Monofocal IOLs, Delivering an Extended Range of Vision to More Patients, at the 2024 ESCRS Read More

Second BVI Market Debut in Less Than Twelve Months Read More

WALTHAM, Mass. — July 18^th, 2023 (GLOBE NEWSWIRE) — BVI, one of the fastest growing surgical ophthalmic businesses in the world, is proud to announce the opening of its new, state of the art facility in Liège, Belgium.  This results in a sizeable increase in BVI’s intraocular lens (IOL) business capacity, unlocking new growth opportunities and reinforcing the company’s environmental, social, and governance (ESG) leadership. Read More

WALTHAM, MA - May 1, 2023 (GLOBE NEWSWIRE) — BVI, a diversified global ophthalmic device company, today announced it has completed enrollment of its U.S. Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal intraocular lens, FINEVISION® HP.  Read More

WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) — BVI, a diversified global ophthalmic device company, today announced certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD). Read More